Review
Published on 04 Jul 2022
Telomere Length Regulation
in Cancer Genetics
Frontiers in Oncology
doi 10.3389/fonc.2022.943622
- 7,151 views
- 19 citations
- Frontiers in Oncology
- Cancer Genetics
- Articles
Type at least 3 characters
1,169 articles
Original Research
Published on 04 Jul 2022
Comprehensive Analysis of the Brain-Expressed X-Link Protein Family in Glioblastoma Multiforme
in Cancer Genetics
Frontiers in Oncology
doi 10.3389/fonc.2022.911942
- 2,883 views
- 4 citations
Original Research
Published on 04 Jul 2022
Mutator-Derived lncRNA Landscape: A Novel Insight Into the Genomic Instability of Prostate Cancer
in Cancer Genetics
Frontiers in Oncology
doi 10.3389/fonc.2022.876531
- 3,528 views
- 2 citations
Original Research
Published on 04 Jul 2022
Identification and Validation of Immune-Related Long Non-Coding RNA Signature for Predicting Immunotherapeutic Response and Prognosis in NSCLC Patients Treated With Immunotherapy
in Cancer Genetics
Frontiers in Oncology
doi 10.3389/fonc.2022.899925
- 3,417 views
- 6 citations
Original Research
Published on 01 Jul 2022
Comprehensive Analysis of Regulatory Networks of m6A Regulators and Reveals Prognosis Biomarkers in Sarcoma
in Cancer Genetics
Frontiers in Oncology
doi 10.3389/fonc.2022.911596
- 2,873 views
- 1 citation
Original Research
Published on 01 Jul 2022
Colorectal Cancer Chemotherapy Drug Bevacizumab May Induce Muscle Atrophy Through CDKN1A and TIMP4
in Cancer Genetics
Frontiers in Oncology
doi 10.3389/fonc.2022.897495
- 4,121 views
- 5 citations
Original Research
Published on 30 Jun 2022
Integrated Analysis Revealing the Senescence-Mediated Immune Heterogeneity of HCC and Construction of a Prognostic Model Based on Senescence-Related Non-Coding RNA Network
in Cancer Genetics
Frontiers in Oncology
doi 10.3389/fonc.2022.912537
- 2,347 views
- 2 citations
Original Research
Published on 30 Jun 2022
Comprehensive Pan-Cancer Analysis of TRPM8 in Tumor Metabolism and Immune Escape
in Cancer Genetics
Frontiers in Oncology
doi 10.3389/fonc.2022.914060
- 3,896 views
- 9 citations
Original Research
Published on 30 Jun 2022
Next-Generation Sequencing Analysis of Gastric Cancer Identifies the Leukemia Inhibitory Factor Receptor as a Driving Factor in Gastric Cancer Progression and as a Predictor of Poor Prognosis
in Cancer Genetics
Frontiers in Oncology
doi 10.3389/fonc.2022.939969
- 4,540 views
- 11 citations
Original Research
Published on 30 Jun 2022
Construction and Validation of a m7G-Related Gene-Based Prognostic Model for Gastric Cancer
in Cancer Genetics
Frontiers in Oncology
doi 10.3389/fonc.2022.861412
- 5,532 views
- 22 citations
Original Research
Published on 30 Jun 2022
The Effects of Cumulative Dose and Polymorphisms in CYP2B6 on the Mitotane Plasma Trough Concentrations in Chinese Patients With Advanced Adrenocortical Carcinoma
in Cancer Genetics
Frontiers in Oncology
doi 10.3389/fonc.2022.919027
- 1,768 views
- 1 citation
Original Research
Published on 30 Jun 2022
Prediction of Gastric Cancer-Related Genes Based on the Graph Transformer Network
in Cancer Genetics
Frontiers in Oncology
doi 10.3389/fonc.2022.902616
- 1,939 views
- 4 citations
Case Report
Published on 30 Jun 2022
A Novel Intergenic Gene Between SLC8A1 and PKDCC-ALK Fusion Responds to ALK TKI WX-0593 in Lung Adenocarcinoma: A Case Report
in Cancer Genetics
Frontiers in Oncology
doi 10.3389/fonc.2022.898954
- 2,466 views
- 2 citations
Systematic Review
Published on 30 Jun 2022
Cumulative Evidence for Relationships Between Multiple Variants in the TERT and CLPTM1L Region and Risk of Cancer and Non-Cancer Disease
in Cancer Genetics
Frontiers in Oncology
doi 10.3389/fonc.2022.946039
- 3,238 views
- 11 citations
Original Research
Published on 29 Jun 2022
miR-200a-3p- and miR-181-5p-Mediated HOXB5 Upregulation Promotes HCC Progression by Transcriptional Activation of EGFR
in Cancer Genetics
Frontiers in Oncology
doi 10.3389/fonc.2022.822760
- 2,924 views
- 7 citations
Methods
Published on 27 Jun 2022
CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients
in Cancer Genetics
Frontiers in Oncology
doi 10.3389/fonc.2022.940523
- 5,839 views
- 27 citations